Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
药物治疗专家意见是一份MEDLINE索引、同行评审的国际期刊，发表了关于新批准/即将上市的化合物（主要为化学/合成来源）的综述文章和原创论文，就这些新药对特定疾病现有药物治疗的可能影响提供专家意见。
Innovative therapies for neovascular age-related macular degeneration
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1636031
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1583209
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1683161
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1626824
Siponimod for the treatment of secondary progressive multiple sclerosis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1551363
Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1543407
Agomelatine for depression: expanding the horizons?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1574747
Current and emerging pharmacotherapy for emergency management of preeclampsia
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1570134
Celecoxib for the treatment of musculoskeletal arthritis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1645123
Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1543408
Bivalirudin during percutaneous coronary intervention in acute coronary syndromes
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1551361
Novel pharmacotherapy for burn wounds: what are the advancements
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1551880
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1649394
Current pharmacotherapeutic options for myasthenia gravis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1682548
Key considerations in the pharmacotherapy of tuberculous meningitis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1638912
Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1589451
Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1610385
Bazedoxifene for the treatment of osteoporosis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1615882
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1560423
Current and promising therapy for primary biliary cholangitis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1601701
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1598970
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1689959
Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1621840
Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1663826
Antimuscarinic drug therapy for overactive bladder syndrome in the elderly – are the concerns justified?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1574749
Pharmacotherapy for hypertension in pregnant patients: special considerations
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1594773
Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1685979
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1559299
Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1583744
An evaluation of tofacitinib for the treatment of psoriatic arthritis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1657404
Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1589453
An evaluation of masitinib for treating systemic mastocytosis
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1645121
Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1559821
Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1669561
An update on the latest chemical therapies for reflux esophagitis in children
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1549224
An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1685496
Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1544244
Zoledronic acid for the treatment of prostate cancer
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1574754
An evaluation of enasidenib for the treatment of acute myeloid leukemia
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1654456
Advances in pharmacotherapy of vestibular and ocular motor disorders
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1610386
Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1541349
The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1656717
Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1681970
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1623879
The pharmacotherapeutic management of pediatric Crohn’s disease
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1659778
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1552942
An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1645124
How can pharmacotherapy impact the quality of life of individuals with high functioning autism?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1663824
What are the main challenges to the pharmacological management of cystinuria?
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2019.1691522
Challenges of selecting pharmacotherapy for macular edema the need for better and combination therapies
来源期刊：Expert Opinion on PharmacotherapyDOI：10.1080/14656566.2018.1559298
